Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

What Dose of Cannabis Is Recommended for Dementia Agitation? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Agitation is one of the most distressing behavioural symptoms in dementia, often involving restlessness, anxiety, or aggression. Because traditional medications such as antipsychotics can increase risks like sedation and stroke, some researchers have explored whether medical cannabis might help calm agitation in certain patients. 

According to NHS guidance, cannabis-based medicinal products (CBMPs) can only be prescribed by specialist doctors for specific conditions such as epilepsy, multiple sclerosis, or chemotherapy-induced nausea, not for dementia-related symptoms. However, emerging trials continue to explore whether cannabinoids, including THC and CBD, might influence mood and behaviour in dementia. 

Can medical cannabis be accessed legally for women’s health?

What The Evidence Shows 

Recent studies, including reviews published in Frontiers in Medicine (Hermush et al., 2022) and PMC (Outen et al., 2021), show inconsistent and modest effects of cannabis for agitation or distress in dementia. Some small clinical trials using CBD-rich oils or balanced THC: CBD sprays reported short-term reductions in agitation, but overall results were not statistically significant compared with placebo. 

Typical study doses ranged from CBD 10–40 mg/day (sometimes with THC below 10 mg/day) or up to four sprays daily of balanced THC: CBD preparations such as Sativex. These doses remain investigational only and are not approved or standardised for dementia. 

NICE’s current position, outlined in NG144 (2025) (Cannabis-based medicinal products), confirms there is insufficient evidence to recommend cannabis-based products for dementia agitation outside of research settings. Safety concerns, including sedation, dizziness, confusion, and falls are particularly relevant for older adults. 

The Alzheimer’s Society also notes that while early studies are exploring cannabinoids in dementia, there is no conclusive evidence that CBD or THC improve symptoms such as agitation or memory problems (Alzheimer’s Society UK: Cannabis, CBD oil and dementia). 

Clinical Bottom Line 

  • There is no NHS-recommended dose of cannabis for dementia agitation. 
  • Clinical trials have tested low-dose CBD or balanced THC: CBD combinations, but findings are inconsistent. 
  • Side effects such as confusion and falls are more likely with THC-containing products. 
  • NICE and NHS do not endorse medical cannabis for dementia symptoms except in research. 
  • Use should be specialist-supervised only within regulatory frameworks. 

About AlleviMed 

AlleviMed provides educational resources to help patients and professionals understand how medical cannabis eligibility is assessed within UK regulations. It supports informed decision-making by explaining the criteria and standards governing specialist prescriptions, without promoting any treatment use. 

Takeaway 

There is currently no recommended or standard dose of cannabis for agitation in dementia. While early studies suggest possible benefits from low-dose CBD-rich preparations, the evidence is not strong or consistent enough for clinical recommendation. NHS and NICE guidance clearly advise against routine prescribing. Anyone considering cannabis-based treatments for dementia should always seek specialist medical advice and avoid unregulated products. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories